Dr Patrick Harris
Dr

Patrick Harris

Email: 
Phone: 
+61 7 334 65476

Background

Dr Patrick Harris is an Infectious Disease Physician, Medical Microbiologist and NHMRC Emerging Leader (EL2) Fellow at The University of Queensland Centre for Clinical Research (UQCCR).

Dr. Harris obtained a BSc in Psychology and Anthropology from Durham University, prior to acquiring his medical degree from University College London Medical School. Following postgraduate training in the UK, he worked as a clinical lecturer at the College of Medicine in Malawi, before completing specialist training in infectious diseases and microbiology in Australia. For his final year of training he was a Senior Visiting Fellow in Infectious Disease at the National University Hospital in Singapore. He completed his PhD in 2018 under the supervision of Prof. David Paterson, and now is a Group Leader at UQCCR, with a research focus on the diagnosis and clinical management of infections caused by multi-drug resistant bacteria

Availability

Dr Patrick Harris is:
Available for supervision

Qualifications

  • Bachelor of Medicine and Surgery and Medical Science, University of London
  • Doctor of Philosophy, The University of Queensland

Research interests

  • Clinical trials

    Assessing the clinical impact of novel antibiotic treatment strategies for bloodstream infections

  • Antibiotic resistance

    Resistance in gram-negative pathogens such as E. coli, Klebsiella and Enterobacter

  • Clinical application of genomics

    Use of whole genome sequencing in clinical microbiology

Research impacts

He has published more than 190 peer-reviewed articles, many as first or senior author, including JAMA, the Lancet, Lancet Infectious Diseases and Clinical Infectious Diseases. He was a lead investigator for the MERINO trial: an international multicentre study to compare carbapenem-sparing treatment options for ESBL and AmpC-producing species. This has been the first large RCT to specifically address this question, using a protocol developed and endorsed by the Australasian Society for Infectious Diseases Clinical Research Network (ASID-CRN). https://clinicaltrials.gov/ct2/show/NCT02176122. This was followed by the MERINO-2 trial: a randomised controlled trial of meropenem versus piperacillin-tazobactam for treatment of bloodstream infections due to AmpC-producing Enterobacter, Citrobacter, Serratia, Providencia and Morganella: https://clinicaltrials.gov/ct2/show/NCT02437045. His other main research interest includes the application of whole genome sequencing to clinical microbiology. He was the clinical lead for the Queensland Genomics Clinical Demonstration Project: Whole genome sequencing to track, treat and prevent nosocomial infections. This project has successfuly integrated a genomics workflow within Queensland health, to support outbreak response and surveillance of hospital acqured multi-drug resistant infections: Hospital acquired infections – Queensland Genomics

Search Professor Patrick Harris’s works on UQ eSpace

258 works between 2009 and 2025
All (258) Journal Article (224) Book Chapter (2) Conference Publication (23) Other Outputs (9)

101 - 120 of 258 works

2022

Journal Article

Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood

Gassiep, Ian, Bauer, Michelle J., Page, Melissa, Harris, Patrick N. A. and Norton, Robert (2022). Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood. Access Microbiology, 4 (3) 000333, 1-6. doi: 10.1099/acmi.0.000333

Comparative evaluation of Panther Fusion and real-time PCR for detection of Burkholderia pseudomallei in spiked human blood

2022

Conference Publication

Burkholderia pseudomallei serology: Worth the hassle?

Gassiep, Ian, Ganeshalingam, Vibooshini, Chatfield, Mark D., Harris, Patrick N.A. and Norton, Robert (2022). Burkholderia pseudomallei serology: Worth the hassle?. RCPA Quality Assurance Programs Presentations, Unknown, Unknown. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2021.12.276

Burkholderia pseudomallei serology: Worth the hassle?

2022

Conference Publication

Can mass spectrometry be used to identify burkholderia pseudomallei directly from spiked blood cultures?

Gassiep, Ian, Bauer, Michelle J., Harris, Patrick N.A. and Norton, Robert (2022). Can mass spectrometry be used to identify burkholderia pseudomallei directly from spiked blood cultures?. Pathology Update 2022, Sydney, NSW Australia, 4-6 March 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/j.pathol.2021.12.274

Can mass spectrometry be used to identify burkholderia pseudomallei directly from spiked blood cultures?

2022

Journal Article

Perioperative transjugular intrahepatic portosystemic shunt is associated with decreased postoperative complications in decompensated cirrhotics undergoing abdominal surgery

Aryan, Mahmoud, McPhail, James, Ravi, Sujan, Harris, Patrick, Allamneni, Chaitanya and Shoreibah, Mohamed (2022). Perioperative transjugular intrahepatic portosystemic shunt is associated with decreased postoperative complications in decompensated cirrhotics undergoing abdominal surgery. American Surgeon, 88 (7), 1613-1620. doi: 10.1177/00031348211069784

Perioperative transjugular intrahepatic portosystemic shunt is associated with decreased postoperative complications in decompensated cirrhotics undergoing abdominal surgery

2022

Journal Article

Pasteurella species bloodstream infections in Queensland, Australia, 2000–2019

Laupland, Kevin B., Stewart, Adam G., Edwards, Felicity, Harris, Patrick, Heney, Claire, George, Narelle, Coulter, Sonali and Paterson, David L. (2022). Pasteurella species bloodstream infections in Queensland, Australia, 2000–2019. European Journal of Clinical Microbiology and Infectious Diseases, 41 (4), 609-614. doi: 10.1007/s10096-022-04411-w

Pasteurella species bloodstream infections in Queensland, Australia, 2000–2019

2022

Journal Article

Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study

McNamara, John F, Harris, Patrick NA, Chatfield, Mark D and Paterson, David L (2022). Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study. International Journal of Infectious Diseases, 114, 34-44. doi: 10.1016/j.ijid.2021.10.047

Long term sepsis readmission, mortality and cause of death following Gram negative bloodstream infection: a propensity matched observational linkage study

2022

Journal Article

Melioidosis: laboratory investigations and association with patient outcomes

Gassiep, Ian, Ganeshalingam, Vibooshini, Chatfield, Mark D., Harris, Patrick N A and Norton, Robert E. (2022). Melioidosis: laboratory investigations and association with patient outcomes. The American Journal of Tropical Medicine and Hygiene, 106 (1), 54-59. doi: 10.4269/ajtmh.21-0548

Melioidosis: laboratory investigations and association with patient outcomes

2022

Journal Article

Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis

Kwok, Michael, Yaxley, William, Ranasinghe, Sachinka, Morton, Leanne, Perera, Sachin, Ponen, Kreyen, Pelecanos, Anita, Britton, Sumudu, Harris, Patrick N. A., Paterson, David L., Esler, Rachel, Hussey, David, Yaxley, John W. and Roberts, Matthew J. (2022). Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis. Journal of Clinical Urology, 17 (6), 205141582210998-587. doi: 10.1177/20514158221099856

Determining risk factors for symptomatic urinary tract infection following trial of void: A retrospective analysis

2022

Journal Article

Performance of the BioFire Blood Culture Identification 2 Panel for the diagnosis of bloodstream infections on blood cultures from the intensive care unit and emergency department

Peri, Anna Maria, Bauer, Michelle J., Bergh, Haakon, Butkiewicz, Dominika, Paterson, David L. and Harris, Patrick N.A. (2022). Performance of the BioFire Blood Culture Identification 2 Panel for the diagnosis of bloodstream infections on blood cultures from the intensive care unit and emergency department. SSRN Electronic Journal. doi: 10.2139/ssrn.4003859

Performance of the BioFire Blood Culture Identification 2 Panel for the diagnosis of bloodstream infections on blood cultures from the intensive care unit and emergency department

2022

Journal Article

CATHAI: cluster analysis tool for healthcare-associated infections

Cuddihy, Thom, Harris, Patrick N. A., Permana, Budi, Beatson, Scott A. and Forde, Brian M. (2022). CATHAI: cluster analysis tool for healthcare-associated infections. Bioinformatics Advances, 2 (1) vbac040, vbac040. doi: 10.1093/bioadv/vbac040

CATHAI: cluster analysis tool for healthcare-associated infections

2022

Journal Article

Genomic analysis of Elizabethkingia species from aquatic environments: evidence for potential clinical transmission

Hem, Sopheak, Jarocki, Veronica M., Baker, Dave J., Charles, Ian G., Drigo, Barbara, Aucote, Sarah, Donner, Erica, Burnard, Delaney, Bauer, Michelle J., Harris, Patrick N.A., Wyrsch, Ethan R. and Djordjevic, Steven P. (2022). Genomic analysis of Elizabethkingia species from aquatic environments: evidence for potential clinical transmission. Current Research in Microbial Sciences, 3 100083, 100083. doi: 10.1016/j.crmicr.2021.100083

Genomic analysis of Elizabethkingia species from aquatic environments: evidence for potential clinical transmission

2022

Journal Article

Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

Isler, Burcu, Aslan, Abdullah Tarık, Akova, Murat, Harris, Patrick and Paterson, David L. (2022). Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections. Expert Review of Anti-Infective Therapy, 20 (11), 1389-1400. doi: 10.1080/14787210.2022.2128764

Treatment strategies for OXA-48-like and NDM producing Klebsiella pneumoniae infections

2021

Journal Article

Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial

Stewart, Adam G, Henderson, Andrew, Bauer, Michelle J, Paterson, David L and Harris, Patrick N A (2021). Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial. JAC-Antimicrobial Resistance, 4 (1) dlab192, dlab192. doi: 10.1093/jacamr/dlab192

Activity of temocillin against third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae bloodstream isolates from a clinical trial

2021

Journal Article

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial

Wright, Hugh, Harris, Patrick N. A., Chatfield, Mark D., Lye, David, Henderson, Andrew, Harris-Brown, Tiffany, Donaldson, Anna and Paterson, David L. (2021). Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial. Trials, 22 (1) 889. doi: 10.1186/s13063-021-05870-w

Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial

2021

Journal Article

A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to Gram negative pathogens. Intended category: systematic review

Henderson, Andrew, Bursle, Evan, Stewart, Adam, Harris, Patrick N. A., Paterson, David, Chatfield, Mark D., Paul, Mical, Dickstein, Yaakov, Rodriguez-Baño, Jesus, Turnidge, John D. and Kahlmeter, Gunnar (2021). A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to Gram negative pathogens. Intended category: systematic review. Clinical Microbiology and Infection, 27 (12), 1746-1753. doi: 10.1016/j.cmi.2021.03.019

A systematic review of antimicrobial susceptibility testing as a tool in clinical trials assessing antimicrobials against infections due to Gram negative pathogens. Intended category: systematic review

2021

Journal Article

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

Stewart, Adam G., Harris, Patrick N. A., Chatfield, Mark D., Littleford, Roberta and Paterson, David L. (2021). Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial. Trials, 22 (1) 301, 301. doi: 10.1186/s13063-021-05206-8

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial

2021

Journal Article

Culture-independent detection systems for bloodstream infection

Peri, Anna Maria, Harris, Patrick N. A. and Paterson, David L. (2021). Culture-independent detection systems for bloodstream infection. Clinical Microbiology and Infection, 28 (2), 195-201. doi: 10.1016/j.cmi.2021.09.039

Culture-independent detection systems for bloodstream infection

2021

Journal Article

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response

Isler, Burcu, Harris, Patrick, Stewart, Adam G. and Paterson, David L. (2021). An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response. Journal of Antimicrobial Chemotherapy, 76 (12), 3327-3328. doi: 10.1093/jac/dkab366

An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa–—authors’ response

2021

Journal Article

Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis

Ling, Weiping, Furuya-Kanamori, Luis, Ezure, Yukiko, Harris, Patrick N. A. and Paterson, David L. (2021). Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis. JAC-Antimicrobial Resistance, 3 (4) dlab157, 1-12. doi: 10.1093/jacamr/dlab157

Adverse clinical outcomes associated with carbapenem-resistant Acinetobacter (CRA) infections: a systematic review and meta-analysis

2021

Conference Publication

Con) Piperacillin-tazobactam for ESBL-producing Enterobacterales

Harris, Patrick N. A. (2021). Con) Piperacillin-tazobactam for ESBL-producing Enterobacterales. 13th International Symposium on Antimicrobial Agents and Resistance (ISAAR 2021), Online, 9-10 September 2021. Amsterdam, Netherlands: Elsevier . doi: 10.1016/j.ijantimicag.2021.106420.27

Con) Piperacillin-tazobactam for ESBL-producing Enterobacterales

Current funding

  • 2025 - 2030
    Comparative effectiveness of Class II/III medical devices to prevent bloodstream infections in central venous catheters: The IVCare adaptive platform RCT
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2030
    IVCare Trial: Comparative Effectiveness of Devices to Prevent Bloodstream Infections in Central Venous Catheters
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2029
    ROAD RCT: Resistance Optimised Antibiotic Dosing in critically ill patients - a Randomised Controlled Trial
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2029
    ROAD RCT: Resistance Optimised Antibiotic Dosing in critically ill patients - a Randomised Controlled Trial
    NHMRC MRFF CTA - Clinical Trials Activity
    Open grant
  • 2025 - 2029
    New diagnostic strategies for antibiotic-resistant infections
    NHMRC Investigator Grants
    Open grant
  • 2024 - 2025
    Testing EBL-1463 (a novel non-beta-lactam PBP inhibitor) against metallo-betalactamase producing Enterobacterales
    Mutabilis SAS
    Open grant
  • 2024 - 2026
    Reducing blood culture contamination with the use of a needle-less blood draw device (PIVO Pro): An adaptive group sequential randomized controlled trial (The PIVO Trial)
    Becton, Dickinson and Company
    Open grant
  • 2024 - 2028
    Unlocking the gut microbiome to track the spread of AMR genes and pathogens
    MRFF - Global Health Initiative
    Open grant
  • 2024 - 2025
    A Rapid, Routine Genomics Service for Clinical Haematology (QLD Health Targeted CRF led by RBWH Metro North Health)
    Metro North Hospital and Health Service
    Open grant
  • 2023 - 2026
    New diagnostic strategies for antibiotic-resistant infections
    Queensland Health Clinical Research Fellowships
    Open grant
  • 2023 - 2025
    Performance of emerging diagnostic techniques for the diagnosis of severe infections in neutropenic patients with haematological malignancies
    Microbio Ltd
    Open grant
  • 2023 - 2027
    Accelerating pathogen detection and antibiotic resistance prediction in children with suspected sepsis
    The Children's Hospital Foundation
    Open grant
  • 2018 - 2030
    Investigator Driven Randomized Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare Associated and Hospital Acquired Gram-negative Blood Stream Infection (the GAME CHANGER trial)
    Shionogi & Company, Limited
    Open grant

Past funding

  • 2023 - 2025
    Development of Wastewater-based epidemiology as a complementary approach for antimicrobial resistance surveillance
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2023 - 2024
    Improving management of fungal infections during blood cancer treatment
    Gilead Australia Fellowship
    Open grant
  • 2022 - 2024
    The 3,000 Genomes project: using machine learning and artificial intelligence for robust culture-independent susceptibility testing
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2022 - 2023
    Non-inferiority of low-level (LLD) versus high-level disinfection (HLD) for elimination of bacteria on contaminated ultrasound transducers: A randomised controlled trial (ASUM grant via MNHHS)
    Metro North Hospital and Health Service
    Open grant
  • 2022 - 2024
    Prediction of catheter associated bloodstream infection and hospital-onset sepsis events in critically ill adults
    Heidi-CSIRO IDR and AMR Projects
    Open grant
  • 2021 - 2022
    Improving Diagnosis, Management and Prevention of Invasive Meningococcal Disease
    Metro North Hospital and Health Service
    Open grant
  • 2021 - 2022
    Peripherally inserted central catheter Innovation to reduce Infections and Clots: the PICNIC trial
    NHMRC Project Grant
    Open grant
  • 2020 - 2021
    Assessing the epidemiology and variation of the variable virulence factor BimABM of Burkholderia pseudomallei in Queensland
    European Society of Clinical Microbiology and Infectious Diseases Study Group Research Grant
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on gut microbiota of hospitalized patients
    Avant Mutual Group Limited
    Open grant
  • 2020
    Rapid detection of resistance genes from Gram-negative bacteria isolated from blood in ICU-admitted patients
    Pathology Queensland - Study, Education & Research Trust Fund
    Open grant
  • 2020 - 2021
    Assessing the effects of new and old antibiotics on the gut microbiome of hospitalized patients
    Metro North Hospital and Health Service
    Open grant
  • 2019 - 2022
    A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of ceftolozane-tazobactam versus meropenem for definitive treatment [...] MERINO-3
    Merck Sharp & Dohme Australia
    Open grant
  • 2019 - 2021
    Virulence and detection of Escherichia coli that cause neonatal meningitis
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2021
    Rapid point-of-care tests for multidrug resistant bacteria tailored for QLD paediatrics
    The Children's Hospital Foundation
    Open grant
  • 2019 - 2022
    A multifaceted approach to the treatment and prevention of antibiotic-resistant bacterial infections
    NHMRC Early Career Fellowships
    Open grant
  • 2019 - 2023
    Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE): A Randomized Controlled Clinical Trial (NHMRC Project Grant led by Monash University)
    Monash University
    Open grant
  • 2019 - 2021
    Peripherally inserted central catheter Innovation to reduCe Infections and Clots: the PICNIC trial (NHMRC Project Grant led by Griffith University)
    Griffith University
    Open grant
  • 2019 - 2020
    Rapid detection of resistance genes from gram-negative bacteria isolated from blood in ICU-admitted patients to enable timely and effective treatment
    Metro North Hospital and Health Service
    Open grant
  • 2018 - 2023
    Cluster randomised trial of a multimodal intervention to reduce antimicrobial use in residential aged care facilities
    NHMRC MRFF - Antimicrobial Resistance Targeted Call for Research
    Open grant
  • 2018 - 2019
    Evaluation of cefiderocol (S-649266) against Burkholderia pseudomallei isolates from Queensland, Australia
    Shionogi & Company, Limited
    Open grant
  • 2018
    Rapid characterisation of pathogens for personalised antimicrobial selection in critically ill patients
    Metro North Hospital and Health Service
    Open grant
  • 2017 - 2018
    Pilot Randomised Controlled Trial of Penicillin versus Flucloxacillin for Definitive Treatment of Invasive Penicillin susceptible Staphylococcus aureas
    Metro North Hospital and Health Service
    Open grant
  • 2015
    Pilot randomised controlled trial of meropenem versus piperacillin-tazobactam for the definitive treatment of bloodstream infections caused by AmpC beta-lactamase producing Enterobacter spp, ...
    Royal Brisbane and Women's Hospital
    Open grant

Availability

Dr Patrick Harris is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Burkholderia pseudomallei: towards rapid diagnosis and management

    Principal Advisor

    Other advisors: Mr Mark Chatfield

  • Doctor Philosophy

    Clinical impact of rapid molecular diagnostics in the diagnosis of bloodstream infections and sepsis

    Principal Advisor

  • Doctor Philosophy

    Novel technologies for the diagnosis of bloodstream infection: performance and clinical application

    Principal Advisor

  • Doctor Philosophy

    New diagnostic strategies for antibiotic-resistant infections

    Principal Advisor

    Other advisors: Associate Professor Adam Irwin

  • Doctor Philosophy

    Clinical and laboratory applications of new and emerging methods of diagnosis of infection

    Associate Advisor

  • Doctor Philosophy

    Clinical and laboratory applications of new and emerging methods of diagnosis of infection

    Associate Advisor

  • Doctor Philosophy

    Genomic approaches to the surveillance and control of multidrug resistant Enterobacterales.

    Associate Advisor

    Other advisors: Dr Brian Forde

  • Doctor Philosophy

    Clinical epidemiology and treatment of central nervous system infections in Asia

    Associate Advisor

  • Doctor Philosophy

    Novel trial design in evaluation of antibiotics.

    Associate Advisor

    Other advisors: Mr Mark Chatfield

  • Doctor Philosophy

    Randomised controlled trial of ceftolozane-tazobactam vs meropenem for bloodstream infections

    Associate Advisor

    Other advisors: Dr Brian Forde, Mr Mark Chatfield

  • Doctor Philosophy

    Clinical epidemiology and treatment of central nervous system infections in Asia

    Associate Advisor

  • Doctor Philosophy

    Accelerating pathogen detection and antibiotic resistance prediction in children with suspected sepsis.

    Associate Advisor

    Other advisors: Associate Professor David Whiley, Associate Professor Adam Irwin

  • Doctor Philosophy

    Treatment Strategies for Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales

    Associate Advisor

    Other advisors: Dr Brian Forde, Mr Mark Chatfield

  • Doctor Philosophy

    Early impact antibiotic therapy for carbapenem resistant organisms, guided by rapid diagnostics

    Associate Advisor

Completed supervision

Enquiries

For media enquiries about Dr Patrick Harris's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au